New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Rodríguez Calvo, Teresa ^a   Ojosnegros, Samuel ^b   Sanz Ramos, Marta ^a,b   García Arriaza, Juan ^b   Escarmís, Cristina ^b   Domingo, Esteban ^b,c   Sevilla, Noemí ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b CSIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOOT AND MOUTH DISEASE VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENETIC COMPLEMENTATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SWINE; T LYMPHOCYTE; VIREMIA; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; IMMUNOLOGY; TREATMENT OUTCOME; VIRUS CULTURE;

ANIMALS; ANTIBODIES, NEUTRALIZING; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENOME, VIRAL; MICE; SERIAL PASSAGE; SWINE; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 77956396768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010414     Document Type: Article

References (61)

1. Mason PW, Grubman MJ, Baxt B (2003) Molecular basis of pathogenesis of FMDV. Virus Res 91: 9-32.
2. Porter AG (1993) Picornavirus nonstructural proteins: emerging roles in virus replication and inhibition of host cell functions. J Virol 67: 6917-6921.
3. Rowlands DJ (2003) Foot-and-mouth disease. Virus Res 91: 1-161.
4. Sobrino F, Domingo E (2004) Foot-and-mouth disease: Current Perspectives; Sobrino FaD E, ed. London: Horizon Press.
5. Garcia-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmis C (2004) Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 78: 11678-11685.
6. Garcia-Arriaza J, Ojosnegros S, Davila M, Domingo E, Escarmis C (2006) Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol 360: 558-572.
7. Manrubia SC, Garcia-Arriaza J, Domingo E, Escarmis C (2006) Long-range transport and universality classes in in vitro viral infection spread. Europhysics Letter 74: 547-553.
8. Pluimers FH, Akkerman AM, van der Wal P, Dekker A, Bianchi A (2002) Lessons from the foot and mouth disease outbreak in The Netherlands in 2001. Rev Sci Tech 21: 711-721.
9. Kitching RP, Hutber AM, Thrusfield MV (2005) A review of foot-and-mouth disease with special consideration for the clinical and epidemiological factors relevant to predictive modelling of the disease. Vet J 169: 197-209.
10. Pereira HG (1981) Foot-and-Mouth disease virus. In: RPG G, ed. Virus diseases of food animals. New York, N.Y.: Academic Press. pp 333-363.
11. Thompson D, Muriel P, Russell D, Osborne P, Bromley A, et al. (2002) Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev Sci Tech 21: 675-687.
12. Domingo E, Mateu MG, Martinez MA, Dopazo J, Moya A, et al. (1990) Virus variation and epidemiology, genetic variability and antigenic diversity of Foot-and-mouth disease virus. In: Kurstak E, Marusyk RG, Murphy SA, Van Regenmortel MHV, eds. Applied Virology Research. New York, NY: Plenum.
13. Domingo E, Ruiz-Jarabo CM, Arias A, Escarmis C (2004) Quasispecies dynamics and evolution of Foot-and-Mouth Disease Virus. In: Sobrino F, Domingo E, eds. Foot-And-Mouth Disease Current perspectives. Norfolk, England: Horizon Bioscience. pp 261-304.
14. Barteling SJ, Cassim NI (2004) Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde. Dev Biol (Basel) 119: 449-455.
15. Doel TR (2003) FMD vaccines. Virus Res 91: 81-99.
16. Salt JS (1993) The carrier state in foot and mouth disease-an immunological review. Br Vet J 149: 207-223.
17. McCullough KC, De Simone F, Brocchi E, Capucci L, Crowther JR, et al. (1992) Protective immune response against foot-and-mouth disease. J Virol 66: 1835-1840.
18. Collen T, Baron J, Childerstone A, Corteyn A, Doel TR, et al. (1998) Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen. Virus Res 56: 125-133.
19. Collen T, Dimarchi R, Doel TR (1991) A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. J Immunol 146: 749-755.
20. Salguero FJ, Sanchez-Martin MA, Diaz-San Segundo F, de Avila A, Sevilla N (2005) Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 332: 384-396.
21. Sanz-Ramos M, Diaz-San Segundo F, Escarmis C, Domingo E, Sevilla N (2008) Hidden virulence determinants in a viral quasispecies in vivo. J Virol 82: 10465-10476.
22. Budowsky EI, Zalesskaya MA (1991) Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone. Vaccine 9: 319-325.
23. Bahnemann HG (1975) Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 47: 47-56.
24. Bahnemann HG (1990) Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 8: 299-303.
25. Sobrino F, Davila M, Ortin J, Domingo E (1983) Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128: 310-318.
26. Eble PL, Bouma A, Weerdmeester K, Stegeman JA, Dekker A (2007) Serological and mucosal immune responses after vaccination and infection with FMDV in pigs. Vaccine 25: 1043-1054.
27. Francis MJ, Black L (1983) Antibody response in pig nasal fluid and serum following foot-and-mouth disease infection or vaccination. J Hyg (Lond) 91: 329-334.
28. Dougherty E, 3rd, Seibold HR, Patty RE (1968) Effects of chronic residence on size and size distribution of plaques of type A foot-and-mouth disease virus in primary calf kidney cell cultures. Am J Vet Res 29: 693-701.
29. Diez J, Hofner M, Domingo E, Donaldson AI (1990) Foot-and-mouth disease virus strains isolated from persistently infected cell cultures are attenuated for mice and cattle. Virus Res 18: 3-7.
30. Beck E, Strohmaier K (1987) Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J Virol 61: 1621-1629.
31. Domingo E, Escarmis C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, et al. (2003) Evolution of foot-and-mouth disease virus. Virus Res 91: 47-63.
32. Mateu MG, Da Silva JL, Rocha E, De Brum DL, Alonso A, et al. (1988) Extensive antigenic heterogeneity of foot-and-mouth disease virus of serotype C. Virology 167: 113-124.
33. Mateu MG, Martinez MA, Rocha E, Andreu D, Parejo J, et al. (1989) Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A 86: 5883-5887.
34. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, et al. (2006) Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol 299: 51-82.
35. Taboga O, Tami C, Carrillo E, Nunez JI, Rodriguez A, et al. (1997) A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol 71: 2606-2614.
36. Kleid DG, Yansura D, Small B, Dowbenko D, Moore DM, et al. (1981) Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science 214: 1125-1129.
37. Tami C, Taboga O, Berinstein A, Nunez JI, Palma EL, et al. (2003) Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J Virol 77: 1219-1226.
38. Kupper H, Keller W, Kurz C, Forss S, Schaller H, et al. (1981) Cloning of cDNA of major antigen of foot and mouth disease virus and expression in E. coli. Nature 289: 555-559.
39. Nicholson (1994) Synthetic Vaccines. Blackwell Scientific Publications.
40. Murphy BR, Chanock RM (1996) Immunization against virus disease. In: Fields BN, Knife DM, Howley PH, eds. Virology. New York: Lippincott-Raven Publishers. pp 467-497.
41. Yang CF, Chen HY, Jorba J, Sun HC, Yang SJ, et al. (2005) Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 79: 12623-12634.
42. Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, et al. (1985) Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314: 548-550.
43. Minor PD (2004) Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol 2: 473-482.
44. Galloway IA (1962) Results of the use of two live attenuated strain vaccines, Rho1 (SAT2 type) and RU11 (SAT1 type) in controlling outbreaks of foot-and-mouth disease. Bulletin de l'office Internationale des Epizooties 57: 748-788.
45. Mason PW, Piccone ME, McKenna TS, Chinsangaram J, Grubman MJ (1997) Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology 227: 96-102.
46. Chinsangaram J, Mason PW, Grubman MJ (1998) Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine 16: 1516-1522.
47. Domingo E, Holland JJ (1997) RNA virus mutations and fitness for survival. Annu Rev Microbiol 51: 151-178.
48. Garcia-Arriaza J, Domingo E, Escarmis C (2005) A segmented form of foot-and-mouth disease virus interferes with standard virus: a link between interference and competitive fitness. Virology 335: 155-164.
49. Rweyemamu MM, Leforban Y (1999) Foot-and-mouth disease and international development. Adv Virus Res 53: 111-126.
50. Chinsangaram J, Moraes MP, Koster M, Grubman MJ (2003) Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol 77: 1621-1625.
51. Moraes MP, Chinsangaram J, Brum MC, Grubman MJ (2003) Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22: 268-279.
52. McInerney GM, King AM, Ross-Smith N, Belsham GJ (2000) Replication-competent foot-and-mouth disease virus RNAs lacking capsid coding sequences. J Gen Virol 81: 1699-1702.
53. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, et al. (2007) A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 81: 10597-10605.
54. Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, et al. (2007) Attenuated measles virus as a vaccine vector. Vaccine 25: 2974-2983.
55. Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, et al. (2009) Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 27: 3299-3305.
56. Billeter MA, Naim HY, Udem SA (2009) Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 329: 129-162.
57. Emonet SF, Garidou L, McGavern DB, de la Torre JC (2009) Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A 106: 3473-3478.
58. Salt JS, Mulcahy G, Kitching RP (1996) Isotype-specific antibody responses to foot-and-mouth disease virus in sera and secretions of ''carrier'' and ''non-carrier'' cattle. Epidemiol Infect 117: 349-360.
59. Mateu MG, Rocha E, Vicente O, Vayreda F, Navalpotro C, et al. (1987) Reactivity with monoclonal antibodies of viruses from an episode of foot-and-mouth disease. Virus Res 8: 261-274.
60. Sierra S, Davila M, Lowenstein PR, Domingo E (2000) Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol 74: 8316-8323.
61. Gonzalez-Lopez C, Arias A, Pariente N, Gomez-Mariano G, Domingo E (2004) Preextinction viral RNA can interfere with infectivity. J Virol 78: 3319-3324.